Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 52Carcinoma, Renal Cell 25Liver Neoplasms 23Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Kidney Neoplasms 11Leukemia, Myeloid, Acute 9Melanoma 8Glioblastoma 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Gliosarcoma 5Urinary Bladder Neoplasms 4Recurrence 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Carcinoma 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leiomyosarcoma 3

Interventions

Temozolomide 2Everolimus 2Capecitabine 2Bevacizumab 2regorafenib 1pazopanib 1motesanib diphosphate 1batifiban 1Sorafenib 1Panobinostat 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulinoma × Sorafenib × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡